{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:19Z","timestamp":1791903319519,"version":"4.3.4"},"reference-count":47,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Inotuzumab ozogamicin (InO) is a humanized, anti-CD22 antibody\u2013drug conjugate with demonstrated use in the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Sinusoidal obstruction syndrome (SOS), a life-threatening complication of hematopoietic stem cell transplant (HSCT), arises from injury to the sinusoidal endothelium and occurs at higher frequency and severity after treatment with InO. Defibrotide is widely used in the treatment of transplant-associated SOS; however, its role in prophylaxis is less clear. In this single-center retrospective analysis, we evaluated all children, adolescents, and young adults with relapsed or refractory B-ALL who underwent HSCT at our institution from 2016 to 2024 and compared outcomes between those who received InO during reinduction before HSCT with those who did not. In addition, we evaluated our institutional practice of employing defibrotide as SOS prophylaxis during HSCT for those with prior receipt of InO. Among children treated with InO, we found that 81% of this heavily pretreated population received InO as the last therapy before HSCT. We found no increase in nonrelapse mortality during HSCT in patients with previous receipt of InO. Among those who received defibrotide prophylaxis, we observed an incidence of transplant-related SOS similar to that observed among patients who did not receive InO during reinduction. Defibrotide prophylaxis was well tolerated, with low rates of adverse events and discontinuation. These results support the use of InO for children with relapsed or refractory B-ALL and suggest that defibrotide prophylaxis may reduce the incidence of SOS during HSCT after InO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020336","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:54:57Z","timestamp":1784296497000},"page":"6395-6406","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-8497","authenticated-orcid":false,"given":"Jonathan D.","family":"Paolino","sequence":"first","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Hebert","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Duncan","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Margossian","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"},{"name":"3Nuvalent Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie E.","family":"Lehmann","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Kapadia","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-2532","authenticated-orcid":false,"given":"Jennifer S.","family":"Whangbo","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"},{"name":"4AstraZeneca, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-8456","authenticated-orcid":false,"given":"Amy K.","family":"Keating","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Alvarez","family":"Calderon","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Horan","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"},{"name":"5Division of Pediatric Hematology-Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Burns","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Davies","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Degar","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda M.","family":"Vrooman","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-4907","authenticated-orcid":false,"given":"Angela M.","family":"Feraco","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-4213","authenticated-orcid":false,"given":"Andrew E.","family":"Place","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Pollard","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7275-7650","authenticated-orcid":false,"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University, Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Kean","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne H. C.","family":"Baumeister","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology\/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"9","key":"2026101310432837500_bib1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.bbmt.2018.05.009","article-title":"Allogeneic stem cell transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 BFM and 2007 International BFM Studies: impact of disease risk on outcomes","volume":"24","author":"Dalle","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026101310432837500_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11899-019-00502-2","article-title":"Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia","volume":"14","author":"Merli","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"2026101310432837500_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026101310432837500_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"issue":"1 suppl","key":"2026101310432837500_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbmt.2008.11.009","article-title":"Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease\/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse","volume":"15","author":"Pulsipher","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"2026101310432837500_bib6","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"2026101310432837500_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2026101310432837500_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026101310432837500_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026101310432837500_bib10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2026101310432837500_bib11","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026101310432837500_bib12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","article-title":"Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease","volume":"109","author":"Kayser","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"2026101310432837500_bib13","doi-asserted-by":"crossref","first-page":"e28718","DOI":"10.1002\/pbc.28718","article-title":"Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia","volume":"68","author":"Contreras","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2026101310432837500_bib14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026101310432837500_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2026101310432837500_bib16","first-page":"1396","article-title":"A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"2026101310432837500_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"9823","key":"2026101310432837500_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"2026101310432837500_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026101310432837500_bib20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"2026101310432837500_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026101310432837500_bib22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"issue":"6","key":"2026101310432837500_bib23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"4","key":"2026101310432837500_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026101310432837500_bib25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.16557","article-title":"Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation","volume":"190","author":"Cairo","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2026101310432837500_bib26","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2352-3026(19)30201-7","article-title":"Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement","volume":"7","author":"Mahadeo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026101310432837500_bib27","first-page":"1122","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European Compassionate-Use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"issue":"12","key":"2026101310432837500_bib28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41409-019-0474-8","article-title":"Systematic review of defibrotide studies in the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS)","volume":"54","author":"Richardson","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2026101310432837500_bib29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","article-title":"The use of defibrotide in blood and marrow transplantation","volume":"2","author":"Richardson","year":"2018","journal-title":"Blood Adv"},{"issue":"13","key":"2026101310432837500_bib30","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"13","key":"2026101310432837500_bib31","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026101310432837500_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","article-title":"Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention","volume":"33","author":"Corbacioglu","year":"2004","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026101310432837500_bib33","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2352-3026(23)00011-X","article-title":"Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial","volume":"10","author":"Grupp","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026101310432837500_bib34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"2026101310432837500_bib35","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22(+) acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"2026101310432837500_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bmt.1701994","article-title":"Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation","volume":"24","author":"Toh","year":"1999","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2026101310432837500_bib37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bmt.1701506","article-title":"Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors","volume":"22","author":"Hasegawa","year":"1998","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026101310432837500_bib38","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bbmt.2020.03.011","article-title":"Incidence of anicteric veno-occlusive disease\/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients","volume":"26","author":"Corbacioglu","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026101310432837500_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/petr.12730","article-title":"Safety of peritoneal and pleural drain placement in pediatric stem cell transplant recipients with severe veno-occlusive disease","volume":"20","author":"Madenci","year":"2016","journal-title":"Pediatr Transpl"},{"issue":"9","key":"2026101310432837500_bib40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat Genet"},{"issue":"40","key":"2026101310432837500_bib41","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/EDBK_278171","article-title":"Cutting to the front of the line: immunotherapy for childhood acute lymphoblastic leukemia","author":"McNeer","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"2026101310432837500_bib42","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3324\/haematol.2021.280433","article-title":"Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"2026101310432837500_bib44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-022-01140-y","article-title":"A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"42","author":"Corbacioglu","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"8","key":"2026101310432837500_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41409-023-02007-2","article-title":"Prevention of veno-occlusive disease\/sinusoidal obstruction syndrome: a never-ending story and no easy answer","volume":"58","author":"Corbacioglu","year":"2023","journal-title":"Bone Marrow Transpl"},{"key":"2026101310432837500_bib46","doi-asserted-by":"crossref","first-page":"1076029620935202","DOI":"10.1177\/1076029620935202","article-title":"A meta-analysis evaluating the incidence of bleeding events with intravenous defibrotide treatment outside the veno-occlusive disease\/sinusoidal obstruction syndrome setting","volume":"26","author":"Tappe","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2026101310432837500_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41409-025-02793-x","article-title":"Defibrotide for prophylaxis of sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"61","author":"Corbacioglu","year":"2026","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"2026101310432837500_bib48","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6395\/2590311\/blooda_adv-2026-020336-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6395\/2590311\/blooda_adv-2026-020336-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:36Z","timestamp":1791902616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6395\/569752\/Allogeneic-HSCT-outcomes-and-impact-of-defibrotide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":47,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020336","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,23]]}}}